In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Centessa ‘Creates Pharma Pipeline Overnight’ Using Novel R&D Approach

Centessa CEO Saurabh Saha Outlines Strategy For New Company Built From A Merger Of 10 Biotechs

Executive Summary

With $250m in series A funding, Cambridge, MA-based Centessa is looking to upend traditional biopharma R&D models. The new company was created through the merger of 10 private biotechs, which will sit under the Centessa umbrella as subsidiaries.

You may also be interested in...



Novo Ventures Remains Bullish After ‘Very Active’ Year

In this latest installment of VC playbook, In Vivo speaks to Naveed Siddiqi, senior partner at Novo Ventures. He discusses the group’s strategy, the European investment outlook for life sciences and how COVID-19 has permanently shifted perceptions of the biopharma industry.

Pandemic Puts A Spotlight On Counterfeit Drugs

As the ongoing COVID-19 pandemic forces health care to go digital, opportunities for fraud have proliferated. In Vivo explores the risks, the steps regulators are taking and how companies are looking to provide innovative solutions to help secure manufacturing supply chains.

Snapshot: March Highlights

A selection of articles you might have missed from March 2021, including exclusive interviews with industry leaders and a deeper dive into drug development and R&D.

Topics

Related Companies

UsernamePublicRestriction

Register

IV124726

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel